• Aleksi Šedo
    Biomedical science is trying to find ways to help patients whom clinical medicine so far cannot help.
    Aleksi Šedo
  • Ondřej Slabý
    Cancer research that really helps is always based on intensive interdisciplinary collaboration.
    Ondřej Slabý
  • Marián Hajdúch
    Our research teams make constant, incremental progress in both diagnosing and treating cancers – and they will never give up in fighting this enemy.
    Marián Hajdúch

Connecting cutting-edge cancer research and oncology education

3nodes

Prague, Brno, Olomouc

5

research programmes

11

research institutes

71

research teams

1shared goal

progress in the fight against cancer

About us


Research of cancers represents about 25% of all biomedical research in the Czech Republic. It is an area that has a long tradition in our country and its current results are, in international comparison, above the average.


Details

News and announcements

2. 7. 2024

Current challenges in neurooncology

On 24-25 June 2024, the Masaryk Memorial Cancer Institute hosted prominent foreign experts focusing on neuro-oncology. The conference "Current challenges in neurooncology: meet the Young Neuro-Oncologist experts", which was also held under the auspices of the National Institute for Cancer Research, featured lectures by Johnny Duerinck, Alessia Pellerino, Marjolein Geurts and Johan A. F. Koekkoek, as well as domestic speakers Tomáš Kazda, Michal Hendrych and Petr Výmola.
19. 6. 2024

Invitation to the Matthew Vander Heiden’s expert lecture

We would like to invite you to the Matthew Vander Heiden’s expert lecture, a leading figure in cancer metabolism and the director of the Koch Institute for Integrative Cancer Biology at MIT, which will give a seminar about their work at Biocev (the main auditorium) next Tuesday, June 25, at 14.00 hours. 

Collaboration


In addition to several large European and Czech scientific infrastructures, the National Institute for Cancer Research will also cooperate with various university hospitals, pharmaceutic or biotechnological companies, patient organisations, and other partners.


Details

 

Key persons